Royalty Pharma (RPRX)
(Delayed Data from NSDQ)
$37.91 USD
+0.03 (0.08%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $37.92 +0.01 (0.03%) 7:38 PM ET
3-Hold of 5 3
B Value B Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
Currently, Royalty Pharma PLC has a PEG ratio of 2.68 compared to the Medical - Biomedical and Genetics industry's PEG ratio of 1.67.
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RPRX 37.91 +0.03(0.08%)
Will RPRX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RPRX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RPRX
Countdown to Royalty Pharma (RPRX) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?
RPRX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say
Royalty Pharma (RPRX) Surpasses Q1 Earnings and Revenue Estimates
Other News for RPRX
Royalty Pharma Q2 2025 Earnings Preview
Here are the major earnings before the open Wednesday
Fidelity Dividend Growth Fund Q2 2025 Commentary
RPRX: Citigroup Raises Price Target for Royalty Pharma | RPRX Stock News
Royalty Pharma (RPRX) Price Target Increased by Citi | RPRX Stock News